MENU
ALPS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ALPS stock forecast, quote, news & analysis

ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 16, 2026

Why Alps Group (ALPS) Stock Is Down 30.6% in the Last 30 Days

Key Takeaways

  • Alps Group (ALPS) shares declined roughly 30.6% over the last 30 days, falling from a close near $1.70 in mid-October to about $1.18 by mid-November.
  • The sell-off accelerated in early November around the company's 1-for-5 reverse stock split, a move commonly tied to exchange-listing compliance concerns.
  • The stock remains in a broader downtrend, down about 34% over the trailing quarter and far below its late-2025 post-listing high.
  • As a micro-cap biotechnology company with a thin float and minimal institutional ownership, ALPS is prone to sharp, high-volatility price swings.
  • Revenue has been growing, but the company continues to operate at a loss, which weighs on investor sentiment.
  • For additional context on valuation and expectations, explore the company's Price Targets, Earnings, and Forecast pages.
  • Investors seeking automated market insights can also explore Trending AI Robots.

Alps Group (ALPS) Company Overview and Market Position

Alps Group Inc is a Malaysia-based, revenue-generating biotechnology platform that integrates research and development, medical services, and wellness solutions for advanced therapies. Operating through segments focused on medical and wellness services, life sciences, and investment holding, the company provides non-surgical and surgical aesthetic services, medical consultation, health screening, cellular therapy, whole-genome sequencing, and pharmacogenomics.

The company's parent entity, Alps Life Sciences Inc, was brought to public markets through a business combination with the special purpose acquisition company Globalink Investment Inc, with ordinary shares beginning to trade on the Nasdaq Global Market under the "ALPS" ticker in October 2025. As a small-cap healthcare name generating the bulk of its revenue in Malaysia, Alps Group is closely watched by investors for its growth trajectory, path toward profitability, and its ability to maintain Nasdaq listing compliance.

Alps Group (ALPS) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ALPS shares fell approximately 30.6%, declining from a closing level near $1.70 in mid-October to around $1.18 by mid-November. The move was concentrated rather than gradual, with the sharpest single-session decline occurring in early November, when the stock dropped from a prior close near $1.60 to below $1.20 amid elevated trading volume.

The near-term weakness extends a longer slide. Over the trailing quarter, the stock is down roughly 34%, and it remains far below its 52-week high near $8.60 reached shortly after its late-2025 market debut. The persistent downtrend reflects a combination of continued operating losses, limited float, and structural corporate actions rather than a single isolated event.

What Drove ALPS Stock Price in the Last 30 Days

The most significant catalyst behind the recent decline was the company's 1-for-5 reverse stock split, announced in late October 2026 and effective in early November. Reverse splits are frequently used by companies trading near the minimum bid-price threshold to restore compliance with exchange listing standards, and they are often interpreted by the market as a signal of financial or operational pressure. The stock experienced heavy selling around the split's effective date.

The listing-compliance backdrop reinforces this interpretation. Alps Group has been flagged for failing to meet Nasdaq continued-listing requirements, and the reverse split appears aimed at addressing the minimum bid-price rule. Combined with the stock's micro-cap profile — a market capitalization of roughly $40 million, a thin public float, and institutional ownership below 1% — the corporate action contributed to outsized downside volatility as limited liquidity amplified price moves.

Fundamentally, the company has reported revenue growth but remains unprofitable, which has kept risk-adjusted sentiment cautious even as the underlying business expands.

What Drove ALPS Stock Performance Over the Last Quarter

The quarterly decline of roughly 34% reflects a broader repricing of a newly public, loss-making micro-cap that has struggled to sustain investor interest since its SPAC-era debut. After an initial surge following its October 2025 listing, ALPS shares have steadily trended lower as the market reassessed the company's scale, cash needs, and path to profitability.

Persistent operating losses, a limited float that leaves the stock vulnerable to large swings, and minimal institutional participation have all contributed to the multi-month downtrend. The reverse stock split in early November marked the latest chapter in this repricing, crystallizing concerns about listing viability and accelerating the decline into the current 30-day window.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a much larger universe of hundreds of bots that trade across thousands of tickers. Only the top-performing and most relevant bots are surfaced in this section, giving visitors a focused view of strategies that have recently stood out. These bots vary widely in approach, trading timeframe, and performance metrics, so the page is designed to help traders compare different automated strategies rather than recommend any single approach. For those interested in systematic, data-driven market analysis, the page offers a practical starting point for exploring how AI trading tools can complement traditional research.

ALPS Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to focus on several key factors. First, whether the reverse stock split successfully restores and sustains Nasdaq listing compliance will be a central concern, as any renewed deficiency could introduce additional uncertainty. Second, the company's ability to convert revenue growth into narrower losses, or eventual profitability, will shape the fundamental outlook.

Additional areas to monitor include the pace of expansion across its cellular therapy, diagnostics, and aesthetic services businesses, capital-raising activity and its dilutive effect on existing shareholders, and broader risk appetite toward speculative, small-cap healthcare names. Given the stock's thin liquidity and high volatility, near-term price movements may remain pronounced and may not always track underlying fundamentals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for ALPS with price predictions
Nov 17, 2026

ALPS in -26.88% downward trend, sliding for three consecutive days on November 12, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALPS declined for three days, in 62 of 79 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALPS as a result. In 22 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 32%.

The Moving Average Convergence Divergence Histogram (MACD) for ALPS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 14 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 27%.

The 10-day moving average for ALPS crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 33%.

The Aroon Indicator for ALPS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPS advanced for three days, in 35 of 71 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.

ALPS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (3.592). P/E Ratio (0.000) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (13.699) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. ALPS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)